MEISi SIGNED
Druggable Small Molecule Inhibitor of MEIS Proteins
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0MEISi project word cloud
Explore the words cloud of the MEISi project. It provides you a very rough idea of what is the project "MEISi" about.
Project "MEISi" data sheet
The following table provides information about the project.
| Coordinator |
MEINOX ILAC TEKNOLOJILERI AS
Organization address contact info |
| Coordinator Country | Turkey [TR] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-12-01 to 2020-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MEINOX ILAC TEKNOLOJILERI AS | TR (SARIYER ISTANBUL) | coordinator | 50˙000.00 |
Map
Project objective
MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries). Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally. Never ending efforts and global targets in tackling these diseases show the importance of the development of more effective therapeutics.
MEISi is a druggable target-based small molecule, developed and validated by Meinox. MEISi inhibits the activity of MEIS protein which plays a critical role in cell metabolism and associated with NCDs. The benefit it presents to the targeted drug discovery market is to provide tools to modulate molecular mechanisms of the NCDs. The massive sizes of oncology and cardiovascular drug markets (USD $ 29.3B globally) indicate the significance of the small molecule drug discovery market which motivates Meinox to target €10M market share in 3 years after commercialization.
Meinox is a deep-tech startup established in 2018 with the main focus on novel and high-level pharmaceutically active ingredients. The company aims to research, develop, produce and market first-in-class, selective drug-like small molecule inhibitors of MEIS, PBX and TGIF2 proteins and their co-factor HOXA9.
Meinox aims to conduct a feasibility study with a risk analysis based on different market regulations. In order to improve the commercialization plan, potential customers of MEISi will be identified and strategies will be developed for each segment by defining proper channels for the MEISi product family. Market entry strategy will be validated by performing market analysis and competitive benchmarking in the target markets.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEISI" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MEISI" are provided by the European Opendata Portal: CORDIS opendata.